News | May 06, 2011

The Case for Maintaining Current Regulations on I-131 Therapy

May 6, 2011 – Two articles in the June issue of The Journal of Nuclear Medicine make a case for maintaining current U.S. Nuclear Regulatory Commission (NRC) regulations on the release of patients who undergo radioactive iodine treatments for thyroid cancer, known as I-131 therapy. Currently, the NRC recommends outpatient treatment for patients receiving radioactive iodine after total or near-total thyroidectomy.

However, several groups have been urging NRC to mandate overnight hospital stays to protect others from a perceived risk of radiation exposure.

The article, "Delayed Initial Radioactive Iodine Therapy Resulted in Poor Survival in Patients with Metastatic Differentiated Thyroid Carcinoma: A Retrospective Statistical Analysis of 198 Cases," evaluated the clinical factors that affected the survival of postoperative patients with differentiated thyroid cancer (DTC) in Japan. According to Tatsuya Higashi, M.D., Ph.D., this is the first report that shows the prognostic value of early performance of radioactive iodine therapy.

Researchers found that the risk of death for patients who received radioactive iodine treatment more than 180 days after a total thyroidectomy was 4.22 times higher than for those treated within the initial 180 days. Several reasons were cited as causing delays in treatment time in Japan, including strict regulation of radioactive materials, a long waiting list for admission to the radioactive iodine therapy ward and delayed referral by the surgeons who performed the total thyroidectomy.

In a related article, "The Real Cost of Theoretic Risk Avoidance: The Need to Challenge Unsubstantiated Concerns About I-131 Therapy," Stanley J. Goldsmith, M.D., cites the Japanese study as a reason to maintain current NRC regulations. If the NRC were to require overnight stays, he reasons, a backlog could result, causing delays in treatment of patients.

He further addresses the concerns of individuals and political representatives seeking to reverse or revise the current NRC guidelines on patient release after I-131 therapy, stating that in spite of many epidemiologic studies completed on the issue, low-dose radiation has never been established to be a causal factor in the development of malignancy. "In no instance," he writes, "is an individual likely to receive radiation exposure in excess of a level deemed exceedingly safe."

The Society of Nuclear Medicine issued a joint statement with the American Thyroid Association, The Endocrine Society and the American Association of Clinical Endocrinologists explaining that based on existing scientific evidence, the current I-131 regulations are safe for patients, their families and the public when radiation safety instructions are followed. However, SNM supports reexamination of this issue if new data emerge that support concerns about public safety.

For more information: jnm.snmjournals.org

Related Content

Global radiotherapy market revenue is set to expand from $7,222.4 million in 2019 to $17,194.4 million by 2030, at an 8.4% CAGR between 2020 and 2030, the key factor driving the market growth is the increasing number of cancer cases, according to the report published by P&S Intelligence.

Image courtesy of Elekta

News | Radiation Therapy | August 06, 2020
August 6, 2020 — Global ...
According to the new market research report "Radiation Dose Management Market by Products & Services (Standalone Solutions, Integrated Solutions, Services), Modality (Computed Tomography, Nuclear Medicine), Application (Oncology, Cardiology, Orthopedic), End User (Hospitals) - Global Forecast to 2025", published by MarketsandMarkets, the radiation dose management market is projected to reach USD 422.65 million by 2025 from USD 220.22 million in 2020, at a CAGR of 13.9%.

Courtesy of MarketsandMarkets Research

News | Radiation Dose Management | August 03, 2020
August 3, 2020 — According to the new market research report "...
Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly welcomes Siemens Healthineers AG’s acquisition of a 100 percent stake in Varian Medical Systems, Inc., a U.S. company active in the area of cancer research and therapy.

Getty Images

News | Radiology Business | August 03, 2020
August 3, 2020 — Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly wel
JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

Table 1. JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

News | Coronavirus (COVID-19) | July 31, 2020
July 31, 2020 — An article published in JAMA...
Older Americans may be receiving cancer screenings not recommended by the U.S. Preventive Services Task Force, according to Penn State College of Medicine researchers.

Getty Images

News | Radiology Imaging | July 31, 2020
July 31, 2020 — Older Americans may be receiving cancer screenings not recommended by the...
It has been estimated that the overwhelming focus on COVID-19 could cause up to 35,000 excess cancer deaths in the UK during the next 12 months, and  Zegami, the Oxford University data visualization spin-out which has worked on several projects focused on the detection, diagnosis, or management of cancer, is calling for greater use of technology to speed up the process of diagnosis and treatment.

Getty Images

News | Radiation Oncology | July 29, 2020
July 29, 2020 — It has been estimated that the overwhelming focus on...
Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

News | Prostate Cancer | July 28, 2020
July 28, 2020 — A study published in 
Zebra Medical Vision announced its sixth FDA 510(k) clearance for its mammography solution, HealthMammo, which has already received a CE mark. Zebra Medical’s algorithm empowers breast radiologists by prioritizing and identifying suspicious mammograms, providing a safety net for radiologists. The suspicious mammograms are identified faster and read earlier than the current “first-in first-out” standard of care. 
News | Breast Imaging | July 27, 2020
July 26, 2020 —  Zebra Medical Vision announced its sixth FDA 510
(a) A schematic of cycloidal computed tomography (not to scale, seen from top); by adding an array of beam stops in front of the detector, the setup is transformed into an edge-illumination x-ray phase-contrast imaging device. (b) A sinogram sampling grid for a rotation-only scheme. (c) A sinogram sampling grid for a cycloidal scheme. The grids are shown for one mask period and a subset of rotation angles; the combination of empty and filled circles shows the grids that would be achieved through fine latera

(a) A schematic of cycloidal computed tomography (not to scale, seen from top); by adding an array of beam stops in front of the detector, the setup is transformed into an edge-illumination x-ray phase-contrast imaging device. (b) A sinogram sampling grid for a rotation-only scheme. (c) A sinogram sampling grid for a cycloidal scheme. The grids are shown for one mask period and a subset of rotation angles; the combination of empty and filled circles shows the grids that would be achieved through fine lateral sampling (requiring dithering); the filled circles show the data that are sampled without dithering.

News | Computed Tomography (CT) | July 24, 2020
July 24, 2020 — A computed tomography (CT) sca